The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo and Uganda is a rapidly evolving crisis that demands urgent attention and action. As of June 6, 2026, the situation is dire, with a total of 534 confirmed cases and 93 deaths reported from both countries, while at least 17 people have recovered. The outbreak is particularly concerning due to its rapid spread, with cases reported from 25 health zones in the Democratic Republic of the Congo and two districts in Uganda. The situation is further complicated by the fact that the virus is zoonotic, with fruit bats suspected to be the natural reservoir, and human infection occurring through close contact with infected wildlife.
The outbreak is concentrated in the Ituri Province of the Democratic Republic of the Congo, which accounts for 94% of confirmed cases. The case fatality rate (CFR) in Ituri is 15%, significantly lower than the CFR in North Kivu, which is 64%. The outbreak has also spread to Uganda, where 19 confirmed cases, including two deaths, have been reported. All cases in Uganda can be linked to travelers from the Democratic Republic of the Congo, with no documented community transmission.
The Bundibugyo virus disease is a severe and often fatal form of Ebola disease caused by the Bundibugyo virus, one of the Orthoebolavirus species. The incubation period for BVD ranges from two to 21 days, and individuals are not infectious until symptom onset. Early symptoms such as fever, fatigue, muscle pain, headache, and sore throat are non-specific, complicating clinical diagnosis and delaying detection. These symptoms then progress to gastrointestinal symptoms, organ dysfunction, and in some cases, haemorrhagic manifestations.
The public health response to the outbreak is multifaceted, involving health authorities in the Democratic Republic of the Congo and Uganda, in collaboration with the World Health Organization (WHO) and partners. Key response activities include interagency coordination, deployment of field teams, delivery of medical supplies, strengthening surveillance, increasing laboratory capacity, infection prevention and control, setting up safe and optimized treatment centers, risk communication and community engagement, and research on potential medical countermeasures.
The WHO has also convened several technical advisory groups, including the Strategic Advisory Group of Experts (SAGE), to assess candidate vaccines and therapeutics for BVD. The risk of the outbreak is assessed as very high in the Democratic Republic of the Congo due to ongoing transmission and the continued expansion of the outbreak into new health zones. The risk in Uganda is assessed as high due to confirmed cross-border spread through imported cases and ongoing epidemiological links along the eastern Democratic Republic of the Congo–western Uganda corridor.
In conclusion, the Bundibugyo virus disease outbreak in the Democratic Republic of the Congo and Uganda is a complex and urgent public health crisis that requires coordinated efforts from national authorities, international organizations, and the global community to prevent further regional spread and ensure an effective public health response.
